Prospects for a parainfluenza virus vaccine

Ewasyshyn, M.; Cates, G A; Jackson, G; Scollard, N.; Symington, Amanda; Klein, Michel

doi:10.1002/ppul.19502308145

Cited by 6 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPIV-3 infections are second only to RSV infections as a cause of serious respiratory tract disease in infants and children. Several strategies for vaccine development, such as the use of live attenuated, inactivated, recombinant, and subunit vaccines, have been investigated (173). The most promising approach involves the development of live attenuated PIV virus candidates, including a bovine PIV-3 vaccine and cold-passaged HPIV-3 vaccines.…”

Section: Respiratory Virusesmentioning

confidence: 99%

Active Immunization in the United States: Developments over the Past Decade

Dennehy

2001

Clin Microbiol Rev

View full text Add to dashboard Cite

SUMMARY The Centers for Disease Control and Prevention has identified immunization as the most important public health advance of the 20th century. The purpose of this article is to review the changes that have taken place in active immunization in the United States over the past decade. Since 1990, new vaccines have become available to prevent five infectious diseases: varicella, rotavirus, hepatitis A, Lyme disease, and Japanese encephalitis virus infection. Improved vaccines have been developed to prevent Haemophilus influenzae type b, pneumococcus, pertussis, rabies, and typhoid infections. Immunization strategies for the prevention of hepatitis B, measles, meningococcal infections, and poliomyelitis have changed as a result of the changing epidemiology of these diseases. Combination vaccines are being developed to facilitate the delivery of multiple antigens, and improved vaccines are under development for cholera, influenza, and meningococcal disease. Major advances in molecular biology have enabled scientists to devise new approaches to the development of vaccines against diseases ranging from respiratory viral to enteric bacterial infections that continue to plague the world's population.

show abstract

Section: Respiratory Virusesmentioning

confidence: 99%

Active Immunization in the United States: Developments over the Past Decade

Dennehy

2001

Clin Microbiol Rev

View full text Add to dashboard Cite

show abstract

Vaccines and infectious disease

Fletcher

Saliou²

2000

Experientia Supplementum

View full text Add to dashboard Cite

Untitled

Josey¹

2001

Int J Pharm Med

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV-3) are the major causes of lower respiratory tract infection in infants and young children. RSV is also responsible for a significant amount of morbidity and mortality in the elderly, the immunosuppressed and those with chronic cardiac or pulmonary disease. Despite extensive research, no effective antiviral therapy or vaccine is currently available for either virus. Over the past 20 years a number of different approaches for developing vaccines for RSV and HPIV-3 have been tested, with varying degrees of success. However, as it is not yet possible to identify one strategy that yields a vaccine preparation suitable for all high-risk populations, a multi-faceted approach to RSV and HPIV-3 vaccine development is still necessary. Ribavirin and immunoglobulin preparations with high titres of RSV-specific neutralizing antibodies are licensed for the treatment and prevention of RSV infection, but neither is cost-effective or easy to administer. New clinically effective agents are needed to diminish the impact of RSV and HPIV-3. This article will review the currently available means for controlling the two viruses, the search for new antiviral agents, and future prospects for preventing and treating RSV and HPIV-3 infections.

show abstract

Prospects for a parainfluenza virus vaccine

Cited by 6 publications

References 9 publications

Active Immunization in the United States: Developments over the Past Decade

Active Immunization in the United States: Developments over the Past Decade

Vaccines and infectious disease

Untitled

Contact Info

Product

Resources

About